KIT V559

CI-VAR-00004545Explore in graph →CIViC 1316

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Digestive System Neoplasm1
KIT V559	Dasatinib + ImatinibSequential	Predictive	D	Supports Sensitivity Response	3	submitted	EID3030 High efficacy toward the imatinib-sensitive KITV559D mutant, with an IC50 of 82 nM. Also, decrease in KIT activation with an increasing dose of dasatinib (while total protein expression remaining unaf… (full text at CIViC) PMID 21953054 · Emile et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.